Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche drug ‘may offer new diabetes treatment option’

Roche drug ‘may offer new diabetes treatment option’

11th February 2010

Roche has announced the results of five phase III clinical trials into its type 2 diabetes treatment taspoglutide.

During the studies, taspoglutide met the primary endpoints of reduction in blood glucose (blood sugar), indicating that the first weekly human GLP-1 analogue may improve treatment options for patients with type 2 diabetes.

Furthermore, the drug was well-tolerated in all five trials, with the most common adverse events among patients being nausea and vomiting.

Hal Barron, global head of product development at Roche, commented: “These Phase III studies have shown that treatment with once weekly taspoglutide leads to significantly improved blood glucose control, consistent weight loss, a minimal risk of hypoglycaemia and manageable safety profile.”

Earlier this month, Roche published its financial results for the whole of 2009, revealing record sales and double-digit growth in operating profit.

Group sales increased to 49.1 billion Swiss francs (29.16 billion pounds) – representing a rise of ten per cent.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.